Carbazole scaffolds in cancer therapy: a review from 2012 to 2018

Journal of Enzyme Inhibition and Medicinal Chemistry

Pål Rongved¹  Samar Issa²  Nicolas Bedel³  Zouhair Bouaziz³  Marc Le Borgne³  Anthony Prandina⁴  Saïd Yous⁵ 

[1] Department of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, Oslo, Norway;Ecole de Biologie Industrielle, EBInnov, Cergy-Pontoise, France;Faculté de Pharmacie - ISPB, EA 4446 Bioactive Molecules and Medicinal Chemistry, SFR Santé Lyon-Est CNRS UMS3453 - INSERM US7, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France;Faculté de Pharmacie - ISPB, EA 4446 Bioactive Molecules and Medicinal Chemistry, SFR Santé Lyon-Est CNRS UMS3453 - INSERM US7, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France;Department of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, Oslo, Norway;Université Lille, Inserm, CHU Lille, UMR-S 1172 JPArc Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, Lille, Franc;

关键词: Carbazole;    cancer;    cytotoxicity;    targeted therapy;    enzyme inhibitors;   

DOI  :  10.1080/14756366.2019.1640692

来源: publisher

【 摘 要 】

For over half a century, the carbazole skeleton has been the key structural motif of many biologically active compounds including natural and synthetic products. Carbazoles have taken an important part in all the existing anti-cancer drugs because of their discovery from a large variety of organisms, including bacteria, fungi, plants, and animals. In this article, we specifically explored the literature from 2012 to 2018 on the anti-tumour activities reported to carbazole derivatives and we have critically collected the most significant data. The most described carbazole anti-tumour agents were classified according to their structure, starting from the tricyclic–carbazole motif to fused tetra-, penta-, hexa- and heptacyclic carbazoles. To date, three derivatives are available on the market and approved in cancer therapy.

【 授权许可】

CC BY